Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases.
Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide. With its"discover-development-partnership"model, the company has forged 10 global collaborations, advancing 9 clinical-stage assets, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Biosion operates across the US, China, and Australia.
Corporate Culture
Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide.
Vision
Delivering Breakthrough Antibody-Based Therapeutics to Patients Globally
Dr. Lei Zheng is Professor of Oncology and Surgery in the Gastrointestinal Oncology Program at the Johns Hopkins University School of Medicine. He is Director of the Pancreatic Cancer Precision Medicine Center of Excellence at Johns Hopkins and Director of the Multidisciplinary Hepato-Panreato-Biliary Research Laboratory. Read More
Dr. Davis has a 35+ year career in the discovery and development of novel therapeutics at major pharmaceutical and biotechnology companies, including the last 20 years at Johnson & Johnson. Read More
Dr. Ghayur has 30+ years of experience leading multi-disciplinary and cross-therapeutic area Biologics discovery programs and developing novel biologics platforms in different organizations – BASF Pharma 1990 – 2001; Abbott Laboratories 2002 – 2013 and AbbVie 2014 – 2021. Read More
Dr. Dixit is an accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, and AstraZeneca. Read More
Yang Yu, Professor at Nanjing University's School of Artificial Intelligence, focuses his research on artificial intelligence (AI), machine learning, and reinforcement learning. Read More
Find us in China, Hong Kong SAR, the United States & Australia
